Mail

UK markets closed

FTSE 100
8,213.49
+41.34(+0.51%)
FTSE 250
20,164.54
+112.21(+0.56%)
AIM
771.53
+3.42(+0.45%)
GBP/EUR
1.1652
-0.0031(-0.26%)
GBP/USD
1.2546
+0.0013(+0.11%)
Bitcoin GBP
51,053.91
+2,781.36(+5.76%)

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

Kane Biotech Inc. (KNE.V)

TSXV - TSXV Real-time price. Currency in CAD

Add to watchlist

0.1300

+0.0050

(+4.00%)

At close: 03:03PM EDT

Currency in CAD

Valuation measures⁴

Market cap (intra-day)	17.14M
Enterprise value	25.64M
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	110.92
Price/book (mrq)	107.98
Enterprise value/revenue	172.12
Enterprise value/EBITDA	-8.25

Trading information

Stock price history

Beta (5Y monthly)	0.55
52-week change ³	30.00%
S&P500 52-week change ³	22.38%
52-week high ³	0.1700
52-week low ³	0.0500
50-day moving average ³	0.1184
200-day moving average ³	0.0883

Share statistics

Avg vol (3-month) ³	182.12k
Avg vol (10-day) ³	65.39k
Shares outstanding ⁵	131.84M
Implied shares outstanding ⁶	131.84M
Float ⁸	84.8M
% held by insiders ¹	34.93%
% held by institutions ¹	0.00%
Shares short (15 Apr 2024) ⁴	17.63k
Short ratio (15 Apr 2024) ⁴	0.07
Short % of float (15 Apr 2024) ⁴	N/A
Short % of shares outstanding (15 Apr 2024) ⁴	0.01%
Shares short (prior month 15 Mar 2024) ⁴	2.63k

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	13 Mar 2017
Ex-dividend date ⁴	N/A
Last split factor ²	1:5
Last split date ³	13 Mar 2017

Financial highlights

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	0.00%
Operating margin (ttm)	-2,248.93%

Management effectiveness

Return on assets (ttm)	-37.06%
Return on equity (ttm)	N/A

Income statement

Revenue (ttm)	148.98k
Revenue per share (ttm)	0.00
Quarterly revenue growth (yoy)	N/A
Gross profit (ttm)	N/A
EBITDA	-3.23M
Net income avi to common (ttm)	-4.56M
Diluted EPS (ttm)	-0.0300
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	749.25k
Total cash per share (mrq)	0.01
Total debt (mrq)	9.26M
Total debt/equity (mrq)	N/A
Current ratio (mrq)	0.34
Book value per share (mrq)	-0.08

Cash flow statement

Operating cash flow (ttm)	-3.22M
Levered free cash flow (ttm)	-1.45M